Topas Therapeutics GmbH (Topas), today announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris (PV), an orphan autoimmune disease. TPM203 is Topas’ most advanced program and the first one from the Company’s proprietary Topas Particle Conjugates (TPC) platform technology to enter the clinic.
Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio
Amphivena Therapeutics, Inc., announced today the closing of a $62 million Series C financing. The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and insiders MPM Capital, funds managed by Tekla Capital Management LLC and Franklin Berger.
Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey
Crescendo Biologics Ltd (Crescendo) today announces that it has signed collaborations with world-renowned oncology research groups at the University of Oxford and the University of Surrey. These collaborations will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow-on pipeline of CD137-directed T cell enhancing programmes.